Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Purchased by Sound Shore Management Inc. CT

Sound Shore Management Inc. CT raised its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 14.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,452,089 shares of the company's stock after purchasing an additional 679,377 shares during the quarter. Teva Pharmaceutical Industries comprises approximately 2.9% of Sound Shore Management Inc. CT's holdings, making the stock its 16th biggest holding. Sound Shore Management Inc. CT owned approximately 0.48% of Teva Pharmaceutical Industries worth $83,799,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Bfsg LLC increased its holdings in Teva Pharmaceutical Industries by 7.8% in the 1st quarter. Bfsg LLC now owns 10,960 shares of the company's stock valued at $168,000 after purchasing an additional 790 shares in the last quarter. Townsquare Capital LLC increased its holdings in Teva Pharmaceutical Industries by 2.1% in the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after purchasing an additional 812 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in Teva Pharmaceutical Industries by 27.7% in the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after purchasing an additional 949 shares in the last quarter. Blair William & Co. IL increased its holdings in Teva Pharmaceutical Industries by 9.4% in the 4th quarter. Blair William & Co. IL now owns 11,232 shares of the company's stock valued at $248,000 after purchasing an additional 963 shares in the last quarter. Finally, Yousif Capital Management LLC increased its holdings in Teva Pharmaceutical Industries by 1.9% in the 1st quarter. Yousif Capital Management LLC now owns 55,986 shares of the company's stock valued at $861,000 after purchasing an additional 1,033 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president owned 9,989 shares of the company's stock, valued at $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.49% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on TEVA shares. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Bank of America raised their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Truist Financial started coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Wall Street Zen downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $24.71.

Teva Pharmaceutical Industries Stock Up 1.2%

Shares of TEVA stock traded up $0.20 during trading hours on Friday, hitting $16.53. 9,205,241 shares of the company were exchanged, compared to its average volume of 9,534,330. The company has a debt-to-equity ratio of 2.59, a quick ratio of 0.74 and a current ratio of 1.03. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80. The business's 50-day simple moving average is $16.93 and its two-hundred day simple moving average is $16.80. The stock has a market capitalization of $18.96 billion, a price-to-earnings ratio of -14.38, a P/E/G ratio of 0.96 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The business had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. During the same quarter last year, the company posted $0.48 earnings per share. The company's quarterly revenue was up 1.9% compared to the same quarter last year. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.